Tricker 2012a.

Study characteristics
Methods	Design: RCT Study dates: not reported Recruitment: no information   Location: Seoul, South Korea Setting: confinement in‐clinic setting
Participants	Number randomised: 72 Characteristics: 25.0% women; mean age 23.8 years; all participants smoked ≥ 10 cigarettes per day; mean FTND score 3.9 for men and 3.3 for women Specialist population: aged 20–50 years Inclusion criteria Currently smoke 10–30 cigarettes per day Aged 20–50 years Only smoked Lark1 cigarettes for 2 weeks prior to study Exclusion criteria Unacceptable medical conditions Abnormal findings on physical examination Use of nicotine or tobacco product other than cigarettes within 3 months prior to screening Alcohol or drug problems Use of any medication other than hormonal contraceptives Pregnant or lactating People of childbearing potential who did not agree to use contraception
Interventions	Randomised (2:2:1 ratio) to use an electronic HTP, continue smoking cigarettes, or become abstinent Heated tobacco arm Device heating method: electronic Device name: EHCSS‐K3, precursor to THS marketed under brand name IQOS Device manufacturer: PMI Other instructions and details: participants were given tobacco sticks Behavioural support: none mentioned Instructions for smoking cessation/switching: switch entirely to heated tobacco use for study period Cigarette smoking arm Other instructions and details: participants were given Lark1 low yield cigarettes Behavioural support: none mentioned Instructions for smoking cessation/switching: continue smoking Lark1 cigarettes for study period Abstinence arm Behavioural support: none mentioned Instructions for smoking cessation/switching: do not smoke cigarettes during study period
Outcomes	Follow‐up time points: 1 week (8 days) Abstinence outcomes: N/A Safety outcomes: biomarkers of exposure to toxins and carcinogens; biomarkers of harm; adverse events; serious adverse events Prevalence/sales outcomes: N/A
Notes	Funding source Tobacco industry funded: quote: "The work reported in all eight parts of this supplement was funded by PMI R&D". Author conflicts of interest Quote: "All authors are or were Philip Morris International (PMI) R&D employees or worked for PMI R&D under contractual agreements".
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details on random sequence generation.
Allocation concealment (selection bias)	Unclear risk	No information.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All outcomes were biological.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information on attrition.
Selective reporting (reporting bias)	Unclear risk	No trial registration or analysis plan.